Nurix Funding & Investors
San Francisco, CA
Nurix, Inc. discovers and develops therapies. The Company develops small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases.
nurixtx.comTotal Amount Raised: $545,900,032
Nurix Funding Rounds
Post Ipo Equity
$175,000,000
Post Ipo Equity
$40,000,000
Post Ipo Equity
$160,400,000
Private Equity
$120,000,000
Private Equity Investors
Foresite CapitalBain Capital Life SciencesWellington ManagementEcoR1 CapitalThird Rock VenturesColumn GroupBoxer CapitalRedmile GroupIPO
Unknown
Series C
$17,000,000
Series B
$25,100,000
Series B Investors
Column GroupThird Rock VenturesSeries Unknown
$5,300,000
Series Unknown Investors
Column GroupThird Rock VenturesSeed
$3,100,000
Seed Investors
Column GroupThird Rock Ventures
Funding info provided by Diffbot.